Major depressive disorder in adolescents aged 12 to 18 years.
Conditions
Interventions
Intervention 1: Intervention group: Intervention description: Participants in this group will receive mirtazapine as an adjunctive treatment in addition to the usual treatment with sertraline. Drug na
Sponsors
Shiraz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
12 Years to 18 Years
Inclusion criteria
Inclusion criteria: Having DSM5 diagnostic criteria for major depressive disorder Age 12 to 18 years Not taking any medication that affects mental status for at least 2 weeks before the study from Persian
Exclusion criteria
Exclusion criteria: The presence of mental retardation The presence of any psychiatric disorder requiring treatment with psychiatric medications, except for major depressive disorder from Persian History of allergy to drugs used in the study Having a serious medical condition, such as heart disease, neurological disease, or a condition requiring surgery from Persian People who have a systolic blood pressure above 125 mm Hg or a resting pulse of less than 60 or above 115 beats per minute. Use of neuroleptic medication in the past 2 weeks Weight under 35 kg Use of any medication or supplement for treatment from Persian History of allergy to mirtazapine and sertraline
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Variable measurement method: To measure the severity of depression, a validated and standardized Persian version of the CDI questionnaire will be used. The questionnaire will be completed by the adolescents themselves and supervised by a researcher or trained psychologist. Also, to increase accuracy, at both time points, a clinical interview based on DSM-5 criteria will be conducted by a child and adolescent psychiatrist, but the main outcome variable will be analyzed only based on the CDI score. Timepoint: Depression severity will be measured at two time points: at the beginning of the study (baseline), before the start of drug treatment, and eight weeks after the start of treatment (end of intervention). Method of measurement: To measure the severity of depression, a validated and standardized Persian version of the CDI questionnaire will be used. The questionnaire will be completed by the adolescents themselves under the supervision of a researcher or trained psychologist. Also, to increase accuracy, at both time points, a clinical interview based on DSM-5 criteria will be conducted by a child and adolescent psychiatrist, but the main outcome variable will be analyzed only based on the CDI score. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFaezeh khosravinia
Shiraz University of Medical Sciences
Outcome results
None listed